BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+46.01%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$7.07B
AUM Growth
+$7.07B
(+37%)
Cap. Flow
+$60.6M
Cap. Flow
% of AUM
0.86%
Top 10 Holdings %
Top 10 Hldgs %
40.22%
Holding
231
New
17
Increased
84
Reduced
52
Closed
23
Top Buys
| 1 |
Edwards Lifesciences
EW
|
$38.5M |
| 2 |
Generation Bio
GBIO
|
$30.2M |
| 3 |
Stryker
SYK
|
$27.2M |
| 4 |
Insulet
PODD
|
$25.1M |
| 5 |
Bristol-Myers Squibb
BMY
|
$23.9M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$84.3M |
| 2 |
Moderna
MRNA
|
$38.9M |
| 3 |
Illumina
ILMN
|
$38.1M |
| 4 |
Intuitive Surgical
ISRG
|
$36.5M |
| 5 |
MacroGenics
MGNX
|
$31.2M |
Sector Composition
| 1 | Healthcare | 96.05% |
| 2 | Industrials | 0.58% |
| 3 | Technology | 0.42% |
| 4 | Communication Services | 0.29% |
| 5 | Financials | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Exelixis
EXEL
$10.1B
| $72.3M | 1.02% |
3,047,500
-927,900
| -23% | -$22M |
|
27
Fate Therapeutics
FATE
$120M
| $67.3M | 0.95% |
1,961,400
+398,200
| +25% | +$13.7M |
|
28
Centene
CNC
$14.3B
| $66.3M | 0.94% |
1,042,747
+232,477
| +29% | +$14.8M |
|
29
Charles River Laboratories
CRL
$8.04B
| $63.8M | 0.9% |
365,833
+34,210
| +10% | +$5.96M |
|
30
Cigna
CI
$80.3B
| $63.2M | 0.89% |
336,726
-12,563
| -4% | -$2.36M |
|
31
Boston Scientific
BSX
$156B
| $60.8M | 0.86% |
1,730,620
+189,395
| +12% | +$6.65M |
|
32
Black Diamond Therapeutics
BDTX
$157M
| $59.2M | 0.84% |
1,403,000
+73,000
| +5% | +$3.08M |
|
|
SAGE
33
DELISTED
Sage Therapeutics
SAGE
| $58.9M | 0.83% |
1,415,504
-2,600
| -0.2% | -$108K |
|
34
Becton Dickinson
BDX
$55.3B
| $58.8M | 0.83% |
245,940
-1,124
| -0.5% | -$269K |
|
35
CRISPR Therapeutics
CRSP
$4.71B
| $58.8M | 0.83% |
800,462
| – | – |
|
|
36
Stryker
SYK
$150B
| $58.4M | 0.83% |
323,942
+151,229
| +88% | +$27.2M |
|
|
37
Edwards Lifesciences
EW
$47.8B
| $54.7M | 0.77% |
791,682
+557,717
| +238% | +$38.5M |
|
38
Baxter International
BAX
$12.7B
| $53.9M | 0.76% |
625,495
+33,574
| +6% | +$2.89M |
|
39
Arvinas
ARVN
$568M
| $53.1M | 0.75% |
1,581,703
+312,400
| +25% | +$10.5M |
|
40
Scholar Rock
SRRK
$3.14B
| $50M | 0.71% |
2,746,106
+31,000
| +1% | +$565K |
|
|
MTEM
41
DELISTED
Molecular Templates, Inc.
MTEM
| $48M | 0.68% |
3,477,240
+566,600
| +19% | +$7.81M |
|
|
HRC
42
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $46.3M | 0.65% |
421,294
+125,815
| +43% | +$13.8M |
|
|
43
Insulet
PODD
$23.9B
| $45M | 0.64% |
231,749
+129,399
| +126% | +$25.1M |
|
|
GWPH
44
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $42.9M | 0.61% |
349,566
+98,600
| +39% | +$12.1M |
|
45
DexCom
DXCM
$29.5B
| $41.6M | 0.59% |
102,705
+1,377
| +1% | +$558K |
|
46
CareDx
CDNA
$727M
| $41.3M | 0.59% |
1,166,839
-110,212
| -9% | -$3.9M |
|
47
Insmed
INSM
$28.8B
| $40.1M | 0.57% |
1,456,174
-157,296
| -10% | -$4.33M |
|
48
Amgen
AMGN
$155B
| $39.6M | 0.56% |
167,963
+36,390
| +28% | +$8.58M |
|
49
Bio-Rad Laboratories Class A
BIO
$8.06B
| $36.1M | 0.51% |
79,871
+17,498
| +28% | +$7.9M |
|
50
Evolent Health
EVH
$1.12B
| $35.8M | 0.51% |
5,028,363
+447,905
| +10% | +$3.19M |
|